Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The reporting period covers the month of April 2026, with the specific transaction date being April 20, 2026. The filing was submitted on April 21, 2026.
Key Financial Metrics and Transaction Details
The filing details a share repurchase executed under a non-discretionary agreement with broker BNP Paribas SA. The transaction metrics are as follows:
- Shares Purchased: 330,000 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 2,134.00 GBp; highest price paid was 2,156.00 GBp.
- Average Price: Volume-weighted average price (VWAP) was 2,141.19 GBp.
- Trading Venues: Purchases were executed across BATE, CHIX, and XLON (London Stock Exchange).
- Treasury Holdings: Following this purchase, GSK holds 260,077,615 ordinary shares in treasury.
- Shares in Issue: 4,056,121,419 ordinary shares (excluding treasury shares).
- Voting Rights: Treasury shares represent 6.41% of total voting rights.
Material Changes and Program Progress
This purchase is part of GSK's existing buyback programme announced on February 17, 2026. Since the commencement of the programme on that date, the company has purchased an aggregate of 20,186,521 ordinary shares. The filing does not provide comparative financial data (revenue, profit, cash flow) as it is a transaction-specific report rather than a periodic financial statement.
Guidance, Outlook, and Risks
The filing contains a standard cautionary statement regarding forward-looking statements. GSK notes that projections are subject to risks and uncertainties that may cause actual results to differ materially. Specific risk factors are referenced in the "Risk Factors" section of GSK's Annual Report on Form 20-F for 2025. No new guidance or management commentary regarding operational outlook is provided in this document.
Investor Verification Checklist
- Verify the total number of shares purchased under the buyback programme since February 17, 2026 (stated as 20,186,521).
- Confirm the current percentage of voting rights held in treasury (stated as 6.41%).
- Review the "Risk Factors" section of the 2025 Form 20-F for details on uncertainties affecting forward-looking statements.
- Check the total number of ordinary shares in issue (4,056,121,419) for denominator calculations regarding shareholder interest notifications.